Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BIOAF NYSE:NUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIOAFBioasis Technologies$0.00$0.00▼$0.00N/A0.19N/AN/ANUSNu Skin Enterprises$7.40+1.0%$7.53$5.65▼$14.62$356.16M1.03503,580 shs21,719 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIOAFBioasis Technologies0.00%0.00%-50.00%-50.00%-75.00%NUSNu Skin Enterprises+1.50%-0.84%-1.11%-29.55%+23.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIOAFBioasis Technologies$0.00$0.00▼$0.00N/A0.19N/AN/ANUSNu Skin Enterprises$7.40+1.0%$7.53$5.65▼$14.62$356.16M1.03503,580 shs21,719 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIOAFBioasis Technologies0.00%0.00%-50.00%-50.00%-75.00%NUSNu Skin Enterprises+1.50%-0.84%-1.11%-29.55%+23.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIOAFBioasis Technologies 0.00N/AN/AN/ANUSNu Skin Enterprises 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest BIOAF and NUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/13/2026NUSNu Skin Enterprises Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/2/2026NUSNu Skin Enterprises Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIOAFBioasis TechnologiesN/AN/AN/AN/AN/AN/ANUSNu Skin Enterprises$1.49B0.24$2.56 per share2.92$16.71 per share0.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIOAFBioasis TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AN/ANUSNu Skin Enterprises$160.20M$3.202.335.70N/A10.79%8.14%4.52%5/7/2026 (Confirmed)Latest BIOAF and NUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026NUSNu Skin Enterprises$0.15N/AN/AN/A$329.70 millionN/A2/13/2026Q4 2025NUSNu Skin Enterprises$0.30$0.29-$0.01$0.29$382.70 million$370.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBIOAFBioasis TechnologiesN/AN/AN/AN/AN/ANUSNu Skin Enterprises$0.243.22%-30.69%7.50%N/ALatest BIOAF and NUS DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/12/2026NUSNu Skin Enterprisesquarterly$0.062.84%2/27/20262/27/20263/11/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIOAFBioasis TechnologiesN/AN/AN/ANUSNu Skin Enterprises0.252.081.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIOAFBioasis TechnologiesN/ANUSNu Skin Enterprises82.84%Insider OwnershipCompanyInsider OwnershipBIOAFBioasis TechnologiesN/ANUSNu Skin Enterprises2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIOAFBioasis TechnologiesN/AN/AN/ANot OptionableNUSNu Skin Enterprises2,80048.13 million46.78 millionOptionableBIOAF and NUS HeadlinesRecent News About These CompaniesNu Skin Enterprises (NUS) Projected to Post Earnings on ThursdayApril 30, 2026 | marketbeat.comTudor Investment Corp ET AL Sells 239,599 Shares of Nu Skin Enterprises, Inc. $NUSApril 16, 2026 | marketbeat.comNu Skin Enterprises (NYSE:NUS) Upgraded to "Hold" at Zacks ResearchApril 15, 2026 | marketbeat.comNu Skin Enterprises to Announce First Quarter 2026 Financial ResultsApril 13, 2026 | businesswire.comNu Skin Launches Prysm iO™: A Revolutionary AI-Powered Platform for Personalized Nutritional WellnessApril 2, 2026 | businesswire.comNu Skin Secures New Five-Year Credit Facilities AgreementMarch 27, 2026 | tipranks.comNu Skin Enterprises Appoints Chelsea Lantz as Interim Chief Financial OfficerMarch 20, 2026 | businesswire.comNu Skin Appoints Chayce Clark as COOMarch 9, 2026 | businesswire.comNu Skin: Patience Is Still AdvisedFebruary 25, 2026 | seekingalpha.comNu Skin Still Has Long-Term Turnaround PotentialFebruary 19, 2026 | seekingalpha.comEstimating The Fair Value Of Nu Skin Enterprises, Inc. (NYSE:NUS)February 17, 2026 | finance.yahoo.comNu Skin Enterprises (NYSE:NUS) Short Interest Falls in Russell 1000February 17, 2026 | kalkinemedia.comKNu Skin Enterprises Inc (NYSE:NUS) In Personal Care Within Russell 1000 Etf Exposure TodayFebruary 17, 2026 | kalkinemedia.comKShould You Sell Your Stake in Nu Skin Enterprises (NUS)?February 16, 2026 | insidermonkey.comNu Skin Enterprises, Inc. (NYSE:NUS) Q4 2025 Earnings Call TranscriptFebruary 14, 2026 | insidermonkey.comNu Skin Enterprises Q4 Earnings Lag Estimates, Revenues Down Y/YFebruary 13, 2026 | zacks.comStonegate Capital Partners Updates Coverage on NU Skin Enterprises Inc. (NUS) 2025 Q4February 13, 2026 | newsfilecorp.comNNu Skin targets placement of 100,000 Prysm iO devices in 2026 as company signals transformation and India expansionFebruary 13, 2026 | seekingalpha.comNu Skin: Q4 Earnings SnapshotFebruary 13, 2026 | stamfordadvocate.comSNu Skin (NUS) Q4 2025 Earnings Call TranscriptFebruary 13, 2026 | fool.comNu Skin Enterprises, Inc. (NUS) Q4 2025 Earnings Call TranscriptFebruary 12, 2026 | seekingalpha.comMedia Sentiment Over TimeBIOAF and NUS Company DescriptionsBioasis Technologies OTCMKTS:BIOAFBioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.Nu Skin Enterprises NYSE:NUS$7.40 +0.07 (+0.95%) As of 10:33 AM Eastern This is a fair market value price provided by Massive. Learn more.Nu Skin Enterprises, Inc., together with its subsidiaries, engages in the development and distribution of various beauty and wellness products worldwide. It offers skin care devices, cosmetics, and other personal care products, including ageLOC LumiSpa and ageLOC LumiSpa iO; and nutricentials skin care products. The company also provides wellness products, such as LifePak nutritional supplements, ageLOC TR90 weight management system, and Beauty Focus Collagen+. In addition, it is involved in the research and product development of skin care products and nutritional supplements. The company sells its products under the Nu Skin, Pharmanex, and ageLOC brands through retail stores, website, digital platforms, and independent direct sellers and marketers, as well as a service center. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
